Global Glucagon-like Peptide-1 Receptor Agonist Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Description

According to our (Global Info Research) latest study, the global Glucagon-like Peptide-1 Receptor Agonist market size was valued at USD 9071.4 million in 2023 and is forecast to a readjusted size of USD 20650 million by 2030 with a CAGR of 12.5% during review period.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

The Global Info Research report includes an overview of the development of the Glucagon-like Peptide-1 Receptor Agonist industry chain, the market status of Solid Tumors (Exenatide, Liraglutide), Blood-related Tumors (Exenatide, Liraglutide), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Glucagon-like Peptide-1 Receptor Agonist.

Regionally, the report analyzes the Glucagon-like Peptide-1 Receptor Agonist markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Glucagon-like Peptide-1 Receptor Agonist market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Glucagon-like Peptide-1 Receptor Agonist market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Glucagon-like Peptide-1 Receptor Agonist industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Exenatide, Liraglutide).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Glucagon-like Peptide-1 Receptor Agonist market.

Regional Analysis: The report involves examining the Glucagon-like Peptide-1 Receptor Agonist market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Glucagon-like Peptide-1 Receptor Agonist market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Glucagon-like Peptide-1 Receptor Agonist:
Company Analysis: Report covers individual Glucagon-like Peptide-1 Receptor Agonist players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Glucagon-like Peptide-1 Receptor Agonist This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Solid Tumors, Blood-related Tumors).

Technology Analysis: Report covers specific technologies relevant to Glucagon-like Peptide-1 Receptor Agonist. It assesses the current state, advancements, and potential future developments in Glucagon-like Peptide-1 Receptor Agonist areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Glucagon-like Peptide-1 Receptor Agonist market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Glucagon-like Peptide-1 Receptor Agonist market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
    Exenatide
    Liraglutide
    Lixisenatide
    Albiglutide
    Others

Market segment by Application
    Solid Tumors
    Blood-related Tumors

Market segment by players, this report covers
    GSK
    Novo Nordisk
    Lily
    Haosoh
    Sanofi
    AstraZeneca

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Glucagon-like Peptide-1 Receptor Agonist product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Glucagon-like Peptide-1 Receptor Agonist, with revenue, gross margin and global market share of Glucagon-like Peptide-1 Receptor Agonist from 2019 to 2024.
Chapter 3, the Glucagon-like Peptide-1 Receptor Agonist competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Glucagon-like Peptide-1 Receptor Agonist market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Glucagon-like Peptide-1 Receptor Agonist.
Chapter 13, to describe Glucagon-like Peptide-1 Receptor Agonist research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Glucagon-like Peptide-1 Receptor Agonist
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Glucagon-like Peptide-1 Receptor Agonist by Type
        1.3.1 Overview: Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type in 2023
        1.3.3 Exenatide
        1.3.4 Liraglutide
        1.3.5 Lixisenatide
        1.3.6 Albiglutide
        1.3.7 Others
    1.4 Global Glucagon-like Peptide-1 Receptor Agonist Market by Application
        1.4.1 Overview: Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Solid Tumors
        1.4.3 Blood-related Tumors
    1.5 Global Glucagon-like Peptide-1 Receptor Agonist Market Size & Forecast
    1.6 Global Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast by Region
        1.6.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Region, (2019-2030)
        1.6.3 North America Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2019-2030)
        1.6.4 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2019-2030)
        1.6.6 South America Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 GSK
        2.1.1 GSK Details
        2.1.2 GSK Major Business
        2.1.3 GSK Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.1.4 GSK Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 GSK Recent Developments and Future Plans
    2.2 Novo Nordisk
        2.2.1 Novo Nordisk Details
        2.2.2 Novo Nordisk Major Business
        2.2.3 Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.2.4 Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Novo Nordisk Recent Developments and Future Plans
    2.3 Lily
        2.3.1 Lily Details
        2.3.2 Lily Major Business
        2.3.3 Lily Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.3.4 Lily Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Lily Recent Developments and Future Plans
    2.4 Haosoh
        2.4.1 Haosoh Details
        2.4.2 Haosoh Major Business
        2.4.3 Haosoh Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.4.4 Haosoh Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Haosoh Recent Developments and Future Plans
    2.5 Sanofi
        2.5.1 Sanofi Details
        2.5.2 Sanofi Major Business
        2.5.3 Sanofi Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.5.4 Sanofi Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Sanofi Recent Developments and Future Plans
    2.6 AstraZeneca
        2.6.1 AstraZeneca Details
        2.6.2 AstraZeneca Major Business
        2.6.3 AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.6.4 AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 AstraZeneca Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Glucagon-like Peptide-1 Receptor Agonist Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Glucagon-like Peptide-1 Receptor Agonist by Company Revenue
        3.2.2 Top 3 Glucagon-like Peptide-1 Receptor Agonist Players Market Share in 2023
        3.2.3 Top 6 Glucagon-like Peptide-1 Receptor Agonist Players Market Share in 2023
    3.3 Glucagon-like Peptide-1 Receptor Agonist Market: Overall Company Footprint Analysis
        3.3.1 Glucagon-like Peptide-1 Receptor Agonist Market: Region Footprint
        3.3.2 Glucagon-like Peptide-1 Receptor Agonist Market: Company Product Type Footprint
        3.3.3 Glucagon-like Peptide-1 Receptor Agonist Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Glucagon-like Peptide-1 Receptor Agonist Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2019-2024)
    5.2 Global Glucagon-like Peptide-1 Receptor Agonist Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2019-2030)
    6.2 North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2019-2030)
    6.3 North America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country
        6.3.1 North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2019-2030)
        6.3.2 United States Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        6.3.3 Canada Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        6.3.4 Mexico Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2019-2030)
    7.2 Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2019-2030)
    7.3 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size by Country
        7.3.1 Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2019-2030)
        7.3.2 Germany Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        7.3.3 France Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        7.3.5 Russia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        7.3.6 Italy Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size by Region
        8.3.1 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Region (2019-2030)
        8.3.2 China Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        8.3.3 Japan Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        8.3.4 South Korea Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        8.3.5 India Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        8.3.7 Australia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2019-2030)
    9.2 South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2019-2030)
    9.3 South America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country
        9.3.1 South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2019-2030)
        9.3.2 Brazil Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        9.3.3 Argentina Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Size by Country
        10.3.1 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2019-2030)
        10.3.2 Turkey Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)
        10.3.4 UAE Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Glucagon-like Peptide-1 Receptor Agonist Market Drivers
    11.2 Glucagon-like Peptide-1 Receptor Agonist Market Restraints
    11.3 Glucagon-like Peptide-1 Receptor Agonist Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Glucagon-like Peptide-1 Receptor Agonist Industry Chain
    12.2 Glucagon-like Peptide-1 Receptor Agonist Upstream Analysis
    12.3 Glucagon-like Peptide-1 Receptor Agonist Midstream Analysis
    12.4 Glucagon-like Peptide-1 Receptor Agonist Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. GSK Company Information, Head Office, and Major Competitors
    Table 6. GSK Major Business
    Table 7. GSK Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 8. GSK Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. GSK Recent Developments and Future Plans
    Table 10. Novo Nordisk Company Information, Head Office, and Major Competitors
    Table 11. Novo Nordisk Major Business
    Table 12. Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 13. Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. Novo Nordisk Recent Developments and Future Plans
    Table 15. Lily Company Information, Head Office, and Major Competitors
    Table 16. Lily Major Business
    Table 17. Lily Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 18. Lily Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Lily Recent Developments and Future Plans
    Table 20. Haosoh Company Information, Head Office, and Major Competitors
    Table 21. Haosoh Major Business
    Table 22. Haosoh Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 23. Haosoh Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. Haosoh Recent Developments and Future Plans
    Table 25. Sanofi Company Information, Head Office, and Major Competitors
    Table 26. Sanofi Major Business
    Table 27. Sanofi Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 28. Sanofi Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. Sanofi Recent Developments and Future Plans
    Table 30. AstraZeneca Company Information, Head Office, and Major Competitors
    Table 31. AstraZeneca Major Business
    Table 32. AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 33. AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. AstraZeneca Recent Developments and Future Plans
    Table 35. Global Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million) by Players (2019-2024)
    Table 36. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Share by Players (2019-2024)
    Table 37. Breakdown of Glucagon-like Peptide-1 Receptor Agonist by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 38. Market Position of Players in Glucagon-like Peptide-1 Receptor Agonist, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 39. Head Office of Key Glucagon-like Peptide-1 Receptor Agonist Players
    Table 40. Glucagon-like Peptide-1 Receptor Agonist Market: Company Product Type Footprint
    Table 41. Glucagon-like Peptide-1 Receptor Agonist Market: Company Product Application Footprint
    Table 42. Glucagon-like Peptide-1 Receptor Agonist New Market Entrants and Barriers to Market Entry
    Table 43. Glucagon-like Peptide-1 Receptor Agonist Mergers, Acquisition, Agreements, and Collaborations
    Table 44. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value (USD Million) by Type (2019-2024)
    Table 45. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Share by Type (2019-2024)
    Table 46. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Forecast by Type (2025-2030)
    Table 47. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2019-2024)
    Table 48. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Forecast by Application (2025-2030)
    Table 49. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2019-2024) & (USD Million)
    Table 50. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2025-2030) & (USD Million)
    Table 51. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2019-2024) & (USD Million)
    Table 52. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2025-2030) & (USD Million)
    Table 53. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2019-2024) & (USD Million)
    Table 54. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2025-2030) & (USD Million)
    Table 55. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2019-2024) & (USD Million)
    Table 56. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2025-2030) & (USD Million)
    Table 57. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2019-2024) & (USD Million)
    Table 58. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2025-2030) & (USD Million)
    Table 59. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2019-2024) & (USD Million)
    Table 60. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2025-2030) & (USD Million)
    Table 61. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2019-2024) & (USD Million)
    Table 62. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2025-2030) & (USD Million)
    Table 63. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2019-2024) & (USD Million)
    Table 64. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2025-2030) & (USD Million)
    Table 65. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Region (2019-2024) & (USD Million)
    Table 66. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Region (2025-2030) & (USD Million)
    Table 67. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2019-2024) & (USD Million)
    Table 68. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2025-2030) & (USD Million)
    Table 69. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2019-2024) & (USD Million)
    Table 70. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2025-2030) & (USD Million)
    Table 71. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2019-2024) & (USD Million)
    Table 72. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2025-2030) & (USD Million)
    Table 73. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2019-2024) & (USD Million)
    Table 74. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2025-2030) & (USD Million)
    Table 75. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2019-2024) & (USD Million)
    Table 76. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2025-2030) & (USD Million)
    Table 77. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2019-2024) & (USD Million)
    Table 78. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2025-2030) & (USD Million)
    Table 79. Glucagon-like Peptide-1 Receptor Agonist Raw Material
    Table 80. Key Suppliers of Glucagon-like Peptide-1 Receptor Agonist Raw Materials
List of Figures
    Figure 1. Glucagon-like Peptide-1 Receptor Agonist Picture
    Figure 2. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type in 2023
    Figure 4. Exenatide
    Figure 5. Liraglutide
    Figure 6. Lixisenatide
    Figure 7. Albiglutide
    Figure 8. Others
    Figure 9. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 10. Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application in 2023
    Figure 11. Solid Tumors Picture
    Figure 12. Blood-related Tumors Picture
    Figure 13. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 14. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 15. Global Market Glucagon-like Peptide-1 Receptor Agonist Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 16. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Region (2019-2030)
    Figure 17. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Region in 2023
    Figure 18. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 19. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 20. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 21. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 22. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 23. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Share by Players in 2023
    Figure 24. Glucagon-like Peptide-1 Receptor Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 25. Global Top 3 Players Glucagon-like Peptide-1 Receptor Agonist Market Share in 2023
    Figure 26. Global Top 6 Players Glucagon-like Peptide-1 Receptor Agonist Market Share in 2023
    Figure 27. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Share by Type (2019-2024)
    Figure 28. Global Glucagon-like Peptide-1 Receptor Agonist Market Share Forecast by Type (2025-2030)
    Figure 29. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Share by Application (2019-2024)
    Figure 30. Global Glucagon-like Peptide-1 Receptor Agonist Market Share Forecast by Application (2025-2030)
    Figure 31. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type (2019-2030)
    Figure 32. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2019-2030)
    Figure 33. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Country (2019-2030)
    Figure 34. United States Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 35. Canada Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 36. Mexico Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 37. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type (2019-2030)
    Figure 38. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2019-2030)
    Figure 39. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Country (2019-2030)
    Figure 40. Germany Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 41. France Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 42. United Kingdom Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 43. Russia Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 44. Italy Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 45. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type (2019-2030)
    Figure 46. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2019-2030)
    Figure 47. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Region (2019-2030)
    Figure 48. China Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 49. Japan Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 50. South Korea Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 51. India Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 52. Southeast Asia Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 53. Australia Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 54. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type (2019-2030)
    Figure 55. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2019-2030)
    Figure 56. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Country (2019-2030)
    Figure 57. Brazil Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 58. Argentina Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 59. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type (2019-2030)
    Figure 60. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2019-2030)
    Figure 61. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Country (2019-2030)
    Figure 62. Turkey Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 63. Saudi Arabia Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 64. UAE Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 65. Glucagon-like Peptide-1 Receptor Agonist Market Drivers
    Figure 66. Glucagon-like Peptide-1 Receptor Agonist Market Restraints
    Figure 67. Glucagon-like Peptide-1 Receptor Agonist Market Trends
    Figure 68. Porters Five Forces Analysis
    Figure 69. Manufacturing Cost Structure Analysis of Glucagon-like Peptide-1 Receptor Agonist in 2023
    Figure 70. Manufacturing Process Analysis of Glucagon-like Peptide-1 Receptor Agonist
    Figure 71. Glucagon-like Peptide-1 Receptor Agonist Industrial Chain
    Figure 72. Methodology
    Figure 73. Research Process and Data Source

Companies Mentioned

GSK
Novo Nordisk
Lily
Haosoh
Sanofi
AstraZeneca